The investigators aim to evaluate the safety and efficacy of in utero hematopoietic stem cell transplantation (IUHSCT) for the treatment of fetuses diagnosed with Fanconi anemia (FA) during pregnancy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Maternal Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0.
Timeframe: From day of treatment to final maternal study visit (30 +/- 15 days after delivery).
Number of Maternal Participants with Serious Adverse Events (SAEs) as Assessed by CTCAE v6.0.
Timeframe: From day of treatment to final maternal study visit (30 +/- 15 days after delivery).
Number of Fetal Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0.
Timeframe: From day of treatment to child's final study visit (24 months after birth).
Number of Fetal Participants with Serious Adverse Events (SAEs) as Assessed by CTCAE v6.0.
Timeframe: From day of treatment to child's final study visit (24 months after birth).